Literature DB >> 11991672

Amiodarone inhibits interleukin 6 production and attenuates myocardial injury induced by viral myocarditis in mice.

Haruyasu Ito1, Koh Ono, Ryousuke Nishio, Shigetake Sasayama, Akira Matsumori.   

Abstract

A recent study has shown that amiodarone inhibits the production of cytokines in vitro. This study was performed to examine the effects of amiodarone on survival, heart weight-to-body-weight ratio (HW/BW), myocardial lesions and cytokines production in a murine model of viral myocarditis induced by the encephalomyocarditis virus (EMCV). Four-week-old male DBA/2 mice were inoculated with the EMCV. To examine its effect on survival and HW/BW on day 14, mice were administered oral amiodarone (30 mg/kg) or the vehicle only once daily, starting 4 days before inoculation of the virus. The effects of amiodarone on histopathologic changes in myocardial lesions and myocardial cytokine production were studied in mice treated with amiodarone (10 mg/kg or 30 mg/kg) or vehicle, and killed day 7. The survival rate on day 14 was significantly higher in the amiodarone-treated mice than in the control mice. The HW/BW, histopathologic score of cellular infiltration and myocardial interleukin 6 concentration were significantly lower in the amiodarone-treated group than in the control group. Likewise, myocardial necrotic area was significantly smaller in the amiodarone group than in the control group. This study suggests that the beneficial effects of amiodarone in viral myocarditis may be mediated by decreasing interleukin 6 production in myocardial tissue. Copyright 2002 Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11991672     DOI: 10.1006/cyto.2001.0996

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  6 in total

1.  Administration of amiodarone during resuscitation is associated with higher tumor necrosis factor-α levels in the early postarrest period in the swine model of ischemic ventricular fibrillation.

Authors:  Scott T Youngquist; James T Niemann; Atman P Shah; Joseph L Thomas; John P Rosborough
Journal:  J Interferon Cytokine Res       Date:  2013-05-09       Impact factor: 2.607

2.  Pleiotropic actions of amiodarone: still puzzling after half a century.

Authors:  Jordi Heijman; Dobromir Dobrev
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-09       Impact factor: 3.000

Review 3.  Inflammation, a link between obesity and atrial fibrillation.

Authors:  Alina Scridon; Dan Dobreanu; Philippe Chevalier; Răzvan Constantin Şerban
Journal:  Inflamm Res       Date:  2015-05-01       Impact factor: 4.575

4.  Amiodarone impairs trafficking through late endosomes inducing a Niemann-Pick C-like phenotype.

Authors:  Elena Piccoli; Matteo Nadai; Carla Mucignat Caretta; Valeria Bergonzini; Claudia Del Vecchio; Huy Riem Ha; Laurent Bigler; Daniele Dal Zoppo; Elisabetta Faggin; Andrea Pettenazzo; Rocco Orlando; Cristiano Salata; Arianna Calistri; Giorgio Palù; Aldo Baritussio
Journal:  Biochem Pharmacol       Date:  2011-08-23       Impact factor: 5.858

Review 5.  Prevalence, Outcomes, and Management of Ventricular Arrhythmias in COVID-19 Patients.

Authors:  Nicola Tarantino; Domenico G Della Rocca; Fengwei Zou; Aung Lin; Andrea Natale; Luigi Di Biase
Journal:  Card Electrophysiol Clin       Date:  2021-10-29

6.  Amiodarone in the COVID-19 Era: Treatment for Symptomatic Patients Only, or Drug to Prevent Infection?

Authors:  Fabian Sanchis-Gomar; Carl J Lavie; Daniel P Morin; Carme Perez-Quilis; Jari A Laukkanen; Marco V Perez
Journal:  Am J Cardiovasc Drugs       Date:  2020-10       Impact factor: 3.283

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.